Incyte Co. (NASDAQ:INCY) – Leerink Swann issued their Q1 2018 EPS estimates for shares of Incyte in a report issued on Friday, according to Zacks Investment Research. Leerink Swann analyst M. Schmidt anticipates that the biopharmaceutical company will earn ($0.33) per share for the quarter. Leerink Swann also issued estimates for Incyte’s Q2 2018 earnings at $0.03 EPS, Q4 2018 earnings at ($0.12) EPS and FY2020 earnings at $1.69 EPS.
Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. The business had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm’s revenue for the quarter was up 41.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.19 EPS.
A number of other research analysts have also commented on INCY. BidaskClub lowered Incyte from a “sell” rating to a “strong sell” rating in a report on Thursday. Oppenheimer reissued a “hold” rating and set a $110.00 price objective (down previously from $120.00) on shares of Incyte in a report on Monday, January 22nd. Goldman Sachs Group began coverage on Incyte in a report on Friday, October 6th. They set a “buy” rating and a $160.00 price objective on the stock. Jefferies Group reissued a “buy” rating on shares of Incyte in a report on Friday, October 6th. Finally, TheStreet lowered Incyte from a “c-” rating to a “d+” rating in a report on Tuesday, December 5th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $143.25.
Shares of Incyte (NASDAQ:INCY) traded down $0.62 during midday trading on Monday, hitting $89.67. The stock had a trading volume of 1,348,510 shares, compared to its average volume of 1,600,000. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. The firm has a market cap of $18,920.00, a price-to-earnings ratio of -112.09 and a beta of 0.74. Incyte has a fifty-two week low of $88.81 and a fifty-two week high of $153.15.
In other news, EVP Vijay K. Iyengar sold 5,000 shares of Incyte stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total transaction of $486,300.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Reid M. Huber sold 696 shares of Incyte stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $98.01, for a total value of $68,214.96. The disclosure for this sale can be found here. Insiders have sold a total of 40,963 shares of company stock worth $4,222,953 in the last three months. 17.70% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in INCY. Tower Research Capital LLC TRC grew its holdings in shares of Incyte by 13.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 108 shares in the last quarter. Seven Eight Capital LP acquired a new stake in shares of Incyte during the 2nd quarter worth approximately $129,000. Sun Life Financial INC grew its holdings in shares of Incyte by 9,069.2% during the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 1,179 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Incyte during the 3rd quarter worth approximately $203,000. Finally, Symphony Asset Management LLC grew its holdings in shares of Incyte by 20.1% during the 2nd quarter. Symphony Asset Management LLC now owns 1,867 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 312 shares in the last quarter. 90.81% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Analysts Offer Predictions for Incyte Co.’s Q1 2018 Earnings (INCY)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/01/incyte-co-expected-to-earn-q1-2018-earnings-of-0-33-per-share-incy.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Get a free copy of the Zacks research report on Incyte (INCY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.